Framed by statements and demands from five industry representatives, two members of the state government yesterday signed a declaration on the “Bavarian Pharmaceutical Summit” - for the first time at a place of top research, in Martinsried.
Martinsried
- “Bavarian Pharmaceutical Summit” is the name of the meetings between the government and industry representatives that took place in 2015, 2019 and 2020. The aim is a better understanding of industrial needs in politics and the implementation of measures that strengthen the industry. In addition to Health Minister Klaus Holetschek, Hubert Aiwanger almost signed the declaration at the IZB, but State Secretary Roland Weigert came because the Minister of Economics was short of time.
Not only was the Martinsried location new, it was also more important than usual against the backdrop of the pandemic. The health sector “can essentially be positioned as the new key economy of the future,” emphasized Holetschek.
In order to avoid drug delivery bottlenecks in the future, more must be done to make Bavarian locations more attractive, for example through favorable taxes and through the use of health data for more effective and faster research.
50 million pharmaceuticals mobilized for Bavaria
Roland Weigert also underlined the goal of “re- and near-shoring”: the relocation of production facilities to Europe.
Even after the last summit, 50 million pharmaceuticals were mobilized for Bavaria.
"The pharmaceutical and biotech industries have achieved outstanding results." But the innovation push must now continue.
“From artificial intelligence to the fight against cancer, it is important to join forces” in order to medically strengthen the resilience of society.
Chantal Friebertshäuser explained for the Association of Research-Based Pharmaceutical Companies: In the health industry, 12.1 percent of the gross domestic product would be generated;
7.4 million employees work there.
Politicians in Bavaria are open-minded.
What is missing is rather the “prevention education culture”, ie the awareness of preventive measures in the population.
Only a third of the diseases treatable
Like Oliver Kirst from the Association of the Bavarian Pharmaceutical Industry, she was in favor of making pseudonymized patient data accessible and evaluating it using artificial intelligence, because only a third of the 30,000 known diseases are treatable.
Kirst went further and called for anonymous data to be collected from patients and hospitals as standard in the future, unless there was active opposition.
Peter Heinrich, who heads the Sinfonie Life Science GmbH in Planegg, spoke for the biotech industry.
He referred to the economic risk of biotech founders and that the "constructive support" of the industry by Bavarian politics should be networked at European level.
“There is an atmosphere of optimism at the Martinsried IZB,” said Bio-M boss Horst Domdey, praising the choice of location.
In December, the ideas will be deepened in working groups.
Andreas Bretting